NCT05899283 is a NA clinical trial of OCI-HF160 in Uremia, sponsored by Chinese PLA General Hospital.

Who is sponsoring NCT05899283?

NCT05899283 is sponsored by Chinese PLA General Hospital.

What drugs are being tested in NCT05899283?

Interventions in NCT05899283: OCI-HF160, FX800HDF.

Is NCT05899283 still recruiting?

NCT05899283 is currently completed. Last updated 12 June 2023.

Last reviewed 2023-06-12 · How we verify

NCT05899283

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Comparative Study of Two Kinds of Hemodialysis Filters

Completed NA Last updated 12 June 2023

What this trial tests

NA trial testing OCI-HF160 in Uremia in 10 participants. Completed in 30 October 2022.

Timeline

1 March 2021

Primary endpoint
31 July 2021

30 October 2022

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 March 2021
Primary completion	31 July 2021
Estimated completion	30 October 2022
Sites	1 location across China

Drugs / interventions tested

OCI-HF160
FX800HDF

Conditions studied

Uremia — all drugs for Uremia →

Sponsor

Chinese PLA General Hospital

Who can join

Adults 18 to 70, any sex, with Uremia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study exploring the expression characteristics of different cells of peripheral blood after exposure to two kinds of hemodialysis filter membrane materials will help to elucidate the key mechanisms of hemodialysis filter coagulation occurrence, which is an important guideline for reducing the occurrence of adverse events in hemodialysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Uremia

Currently open trials in the same condition.

NCT03629977 — Timing of Renal Replacement Therapy in the Critically Ill Patients · recruiting
NCT06233838 — Multi-center Clinical Study on Hemoperfusion of KHA80 · NA · recruiting

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05899283 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
Last refreshed: 12 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05899283.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing